• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    1/27/23 8:06:13 AM ET
    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Redhill Biopharma (NASDAQ:RDHL) stock rose 35.0% to $0.25 during Friday's pre-market session. The market value of their outstanding shares is at $22.6 million.
    • Akanda (NASDAQ:AKAN) stock moved upwards by 29.1% to $0.36. The market value of their outstanding shares is at $12.3 million.
    • Bionomics (NASDAQ:BNOX) shares increased by 19.54% to $5.26. The market value of their outstanding shares is at $39.5 million.
    • Senti Biosciences (NASDAQ:SNTI) shares rose 13.66% to $2.08. The market value of their outstanding shares is at $91.2 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock increased by 13.15% to $6.45. The company's market cap stands at $256.3 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares rose 13.06% to $2.25. The market value of their outstanding shares is at $18.4 million.

    Losers

    • ContraFect (NASDAQ:CFRX) shares decreased by 21.8% to $0.07 during Friday's pre-market session. The company's market cap stands at $3.1 million.
    • Allied Healthcare Prods (NASDAQ:AHPI) shares declined by 12.5% to $0.63. The company's market cap stands at $2.5 million.
    • Biotricity (NASDAQ:BTCY) shares fell 9.35% to $0.8. The market value of their outstanding shares is at $41.7 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) stock declined by 9.33% to $1.75. The company's market cap stands at $5.4 million.
    • NewAmsterdam Pharma (NASDAQ:NAMS) stock decreased by 9.08% to $12.33. The market value of their outstanding shares is at $1.0 billion.
    • GeneDx Holdings (NASDAQ:WGS) stock fell 8.14% to $0.35. The market value of their outstanding shares is at $135.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $AHPI
    $AKAN
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    NewAmsterdam Pharma Company N.V.
    $NAMS
    10/20/2025$52.00Buy
    H.C. Wainwright
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    Senti Biosciences Inc.
    $SNTI
    10/14/2025$12.00Buy
    H.C. Wainwright
    NewAmsterdam Pharma Company N.V.
    $NAMS
    8/25/2025$45.00Overweight
    Wells Fargo
    NewAmsterdam Pharma Company N.V.
    $NAMS
    7/17/2025$27.00Neutral
    Goldman
    GeneDx Holdings Corp.
    $WGS
    7/9/2025$110.00Overweight
    Piper Sandler
    NewAmsterdam Pharma Company N.V.
    $NAMS
    6/17/2025$42.00Buy
    Citigroup
    More analyst ratings

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Topper James N bought $15,639 worth of Ordinary Shares (660 units at $23.70) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/17/25 5:22:34 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Topper James N bought $31,487 worth of Ordinary Shares (1,260 units at $24.99) (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    9/10/25 5:19:10 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GeneDx to Participate in Upcoming Investor Conferences

    GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Boston, MA Fireside Chat: Monday, March 2 at 1:50 p.m. ET Barclays 28th Annual Global Healthcare Conference Miami Beach, FL Presentation: Wednesday, March 11 at 3:00 p.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.genedx.com/news-events/events. About GeneDx GeneDx's (NASDAQ:WGS) mission is to empower everyone to live their heal

    2/25/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Joint U.S. Commercialization of RedHill's Talicia® Commences

    The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reachFocused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1, THI and Cumberland will manage the launch and ongoing joint commercialization activitiesH. pylori infection affects 35% of the U.S. adult population and an estimated 1.6 million U.S. patients are treated annually2. Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H

    2/25/26 7:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    SEC Filings

    View All

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    2/25/26 7:01:02 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by NewAmsterdam Pharma Company N.V.

    144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    2/24/26 4:22:51 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by GeneDx Holdings Corp.

    S-8 - GeneDx Holdings Corp. (0001818331) (Filer)

    2/23/26 8:29:25 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Kastelein Johannes Jacob Pieter sold $1,605,998 worth of Ordinary Shares (45,481 units at $35.31), decreasing direct ownership by 46% to 53,500 units (SEC Form 4)

    4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

    2/24/26 4:40:11 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Jacoby Vanessa

    3 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)

    2/9/26 5:00:02 PM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Dechairo Bryan sold $510,874 worth of shares (5,961 units at $85.70), closing all direct ownership in the company (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    2/6/26 4:19:01 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    H.C. Wainwright resumed coverage on NewAmsterdam Pharma with a new price target

    H.C. Wainwright resumed coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $52.00

    10/20/25 8:45:44 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on GeneDx with a new price target

    Canaccord Genuity initiated coverage of GeneDx with a rating of Buy and set a new price target of $155.00

    10/20/25 8:45:12 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

    Renowned physician–scientist and healthcare innovator to lead GeneDx's vision for a new era of lifelong health informed by genomics GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx's vision to unlock the power of genomics to help every person live their healthiest life. As Chief Precision Medicine Officer, Dr. Lee will lead GeneDx's work to empower customizable precision medicine as the standard of care, leveraging the power of genomics to predict, prevent, and optimize health outcomes throughout a person's lifetime. Precision medicine c

    10/14/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

    Truveta co‑founder and longtime Microsoft leader joins Executive Leadership Team GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx's next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company's long-term vision of enabling precision medicine. As Chief Business Officer, Gurry will architect and operate GeneDx's strategic business operations and partnership models that open doors and create opportunities t

    9/30/25 8:00:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company's Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partnership across investment, research and development, manufacturing and clinical collaboration at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, from 3:10 – 3:40 PM ET. Live au

    2/24/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

    Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t

    2/23/26 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based a

    2/20/26 8:50:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AHPI
    $AKAN
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care